South Korea · Delayed Price · Currency is KRW GemVax&KAEL Statistics
Total Valuation
GemVax&KAEL has a market cap or net worth of KRW 581.96 billion. The enterprise value is 611.90 billion.
| Market Cap | 581.96B |
| Enterprise Value | 611.90B |
Important Dates
The last earnings date was Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GemVax&KAEL has 43.95 million shares outstanding. The number of shares has increased by 5.56% in one year.
| Current Share Class | 43.95M |
| Shares Outstanding | 43.95M |
| Shares Change (YoY) | +5.56% |
| Shares Change (QoQ) | +1.04% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 4.36% |
| Float | 32.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.66 |
| PB Ratio | 7.21 |
| P/TBV Ratio | 7.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.00 |
| EV / EBITDA | 136.22 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.18, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.18 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 5.73 |
| Debt / FCF | -32.30 |
| Interest Coverage | 0.94 |
Financial Efficiency
Return on equity (ROE) is -6.43% and return on invested capital (ROIC) is 2.93%.
| Return on Equity (ROE) | -6.43% |
| Return on Assets (ROA) | 2.22% |
| Return on Invested Capital (ROIC) | 2.93% |
| Return on Capital Employed (ROCE) | 4.63% |
| Weighted Average Cost of Capital (WACC) | 8.42% |
| Revenue Per Employee | 480.30M |
| Profits Per Employee | -21.67M |
| Employee Count | 182 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 5.42 |
Taxes
In the past 12 months, GemVax&KAEL has paid 439.57 million in taxes.
| Income Tax | 439.57M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.75% in the last 52 weeks. The beta is 0.75, so GemVax&KAEL's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -77.75% |
| 50-Day Moving Average | 21,510.00 |
| 200-Day Moving Average | 35,645.50 |
| Relative Strength Index (RSI) | 27.02 |
| Average Volume (20 Days) | 315,337 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GemVax&KAEL had revenue of KRW 87.41 billion and -3.94 billion in losses. Loss per share was -94.10.
| Revenue | 87.41B |
| Gross Profit | 35.77B |
| Operating Income | 5.98B |
| Pretax Income | -3.51B |
| Net Income | -3.94B |
| EBITDA | 10.22B |
| EBIT | 5.98B |
| Loss Per Share | -94.10 |
Balance Sheet
The company has 28.66 billion in cash and 58.59 billion in debt, with a net cash position of -29.94 billion or -681.04 per share.
| Cash & Cash Equivalents | 28.66B |
| Total Debt | 58.59B |
| Net Cash | -29.94B |
| Net Cash Per Share | -681.04 |
| Equity (Book Value) | 80.73B |
| Book Value Per Share | 1,894.97 |
| Working Capital | 8.22B |
Cash Flow
In the last 12 months, operating cash flow was -639.57 million and capital expenditures -1.17 billion, giving a free cash flow of -1.81 billion.
| Operating Cash Flow | -639.57M |
| Capital Expenditures | -1.17B |
| Depreciation & Amortization | 4.23B |
| Net Borrowing | 15.12B |
| Free Cash Flow | -1.81B |
| FCF Per Share | -41.26 |
Margins
Gross margin is 40.92%, with operating and profit margins of 6.85% and -4.51%.
| Gross Margin | 40.92% |
| Operating Margin | 6.85% |
| Pretax Margin | -4.01% |
| Profit Margin | -4.51% |
| EBITDA Margin | 11.69% |
| EBIT Margin | 6.85% |
| FCF Margin | n/a |
Dividends & Yields
GemVax&KAEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.56% |
| Shareholder Yield | -5.56% |
| Earnings Yield | -0.68% |
| FCF Yield | -0.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GemVax&KAEL has an Altman Z-Score of 11.46 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.46 |
| Piotroski F-Score | 6 |